<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04027907</url>
  </required_header>
  <id_info>
    <org_study_id>Plt activity by flowcytometry</org_study_id>
    <nct_id>NCT04027907</nct_id>
  </id_info>
  <brief_title>Platelet Activity in T2DM Using Flowcytometry</brief_title>
  <official_title>Platelet Activity in Type 2 Diabetic Patients Using Flowcytometry in Relation to Macrovascular Complication.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -Describe platelet activity in type 2 diabetes as a participant in vascular inflammation.&#xD;
      -Compare platelet activity in patients with type 2 diabetes mellitus versus healthy controls.&#xD;
      -Study and describe platelet activity in patients with type 2 diabetes mellitus in&#xD;
      association with ischemic cardiovascular disease in relation to duration of diabetes mellitus&#xD;
      .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type2diabetes mellitus(T2DM)is most prevalent and costly chronic disease(Leon et al&#xD;
      2015).according to IDF a further increase to 642million diagnosed individual by2040(Ogurtsova&#xD;
      et al 2017).the major cause of morbidity and mortality in DM is macrovascular&#xD;
      complications.75% of diabetic patients die of cardiovascular disease(CVD)( Ridker et&#xD;
      al2017).Platelets are one of blood cells 1,5-3um in size and survive 8-10days ,their function&#xD;
      extended beyond homestasis and thrombosis to be an active participant in intiating and&#xD;
      sustaining vascular inflammation as well as in prothrombotic complications of CVD(Festa et&#xD;
      al2002).platelets are hyperactive in diabetic patients ,the coagulation cascade is&#xD;
      dysfunctional ,platelet inT2DM adhere to vascular endothelium and aggregate more readily than&#xD;
      those in healthy people(Pretorius2011)*.platelets are activated when they are in contact with&#xD;
      damaged vascular endothelium , once activated they secrete awide spectrum of inflammatory&#xD;
      mediators , once they are activated , they intiate reactions by changes in the level of&#xD;
      expression of surface glycoproteins(GP)results , which act as receptors for platelet agonist&#xD;
      and for adhesive proteins involved in platelet aggregation(Pretorius etal2015)**.platelet&#xD;
      activity can be measured by flow cytometry ,as flow cytometry allows the simultaneous&#xD;
      detection of surface antigens in a sensitive and specific manner , it is therefore possible&#xD;
      to examine aspects of the platelet membrane activity . the available platelet markers&#xD;
      areCD41a marker forGP2b ,CD42 a marker for GP1b.both are used for platelet identification.(&#xD;
      Pretorius et al 2017)***.CD62 a marker for P-selectin ,anti-CD62 react with alpha granule&#xD;
      membrane protein which is expressed on the surface of activated platelet.CD63 a marker for&#xD;
      GP4 and anti-CD63 react with lysosomal granule-membrane glycoprotein that is expressed on&#xD;
      surface of activated platelet. CD62andCD63 are markers of platelet activation (Ibrahim et al&#xD;
      2017).knowing the major role of platelets in inflammatory and healing process in the vascular&#xD;
      system especially in diabetic patients ,created the urgency to study the impact of platelet&#xD;
      activity in diabetic patients whom has macrovascular risk using flowcytometry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet activity in type 2 diabetic patients using flowcytometry in relation to macrovascular complication.</measure>
    <time_frame>Baseline</time_frame>
    <description>Dedect platelet activity by surface expression of platelet receptors determined by flowcytometry using different monoclonal antibodies (CD62 and CD63)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet activity in type 2 diabetic patients using flowcytometry in relation to macrovascular complication.</measure>
    <time_frame>Baseline</time_frame>
    <description>Dedect platelet number by surface expression of platelet receptors determined by flowcytometry using different monoclonal antibodies (CD41 and CD42)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Platelet Activity in T2DM Using Flowcytometry</condition>
  <arm_group>
    <arm_group_label>T2DM</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Flowcytometry</intervention_name>
    <description>detect platelet activity in T2DM by surface expression of platelet receptors determined by flowcytometry using different monoclonal antibodies (CD62 and CD63).</description>
    <arm_group_label>T2DM</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Diabetic patients will be recruited from Internal medicine department and Diabetes out&#xD;
        patient clinic in Assuit University Hospital.&#xD;
&#xD;
        Controls will be health workers and paramedicals in Assuit university hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The study will include patient with type II diabetes at age of 30-60 years old with or&#xD;
             without ischemic cardiovascular disease. . Controls will be healthy individuals with&#xD;
             normal blood glucose level of same matched age group.&#xD;
&#xD;
        Exclusion Criteria: 1)Type1Diabetes mellitus. 2)Hypertensive patients. 3)patients with&#xD;
        renal impairment. 4) patients with hepatic impairment. 5)patients with thrombocytopenia.&#xD;
        6)Pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>hanaa ahmed, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fatema Abd-EL Moez, MD</last_name>
    <phone>00201006564000</phone>
    <email>Fatmaelosily@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mai mohamed, MD</last_name>
    <phone>00201223971678</phone>
    <email>maialy24983@gmail.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Castaigne F, Liber E, Carbillet L, Boulet M, Riel RR. [New procedure for protein spinning: the hydrodynamic process]. Ann Nutr Aliment. 1978;32(2-3):217-31. French.</citation>
    <PMID>707914</PMID>
  </results_reference>
  <results_reference>
    <citation>Gulati RB, Wadia RS, Shaikh RA, Soares PM, Grant KB. Precordial mapping in acute myocardial infarction. Jpn Heart J. 1977 Jul;18(4):447-56.</citation>
    <PMID>909154</PMID>
  </results_reference>
  <results_reference>
    <citation>Gheorghiu T, BÄƒdescu A. [Dynamcis of immunocompetent cells in the contralateral lymph node in grafted cancer, under the influence of some factors stimulating and inhibiting the CNS in rats]. Rev Med Chir Soc Med Nat Iasi. 1976 Jan-Mar;80(1):79-84. Romanian.</citation>
    <PMID>9680</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 18, 2019</study_first_submitted>
  <study_first_submitted_qc>July 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2019</study_first_posted>
  <last_update_submitted>July 18, 2019</last_update_submitted>
  <last_update_submitted_qc>July 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Hanaa M Ahmed</investigator_full_name>
    <investigator_title>HMAmed</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

